<DOC>
	<DOCNO>NCT00120861</DOCNO>
	<brief_summary>This study conduct compare safety , effectiveness tolerance valopicitabine ( NM283 ) use alone valopicitabine use together pegylated interferon hepatitis C treatment failure patient . These result compare result treatment pegylated interferon plus ribavirin , current standard therapy treatment hepatitis C viral infection .</brief_summary>
	<brief_title>Valopicitabine Alone Together With Pegylated Interferon Patients With Chronic Hepatitis C Who Have Failed Respond Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Documented clinical history compatible chronic hepatitis C compensate liver disease Failed response previous hepatitis C therapy pegylated interferon/ribavirin Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient coinfected hepatitis B HIV Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Genotype-1</keyword>
	<keyword>Previously fail treatment</keyword>
</DOC>